A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2)
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Sponsor: Janssen Research & Development, LLC
A PHASE1 clinical study on Carcinoma, Non-Small-Cell Lung, this trial is ongoing. The trial is conducted by Janssen Research & Development, LLC and has accumulated 64 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
64 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
▶ Show 59 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
-
Mar 2025 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE1
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Mar 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE1
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE1
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE1
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE1
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE1
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE1
-
Apr 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE1
-
Dec 2019 — Mar 2020 [monthly]
Recruiting PHASE1
-
Oct 2019 — Dec 2019 [monthly]
Recruiting PHASE1
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Beijing, China , Berlin, Germany , Bordeaux, France , Boston, United States , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Chūōku, Japan and 56 more locations